MX2022007162A - Forma de dosificacion que comprende un agente alcalino y una capa de revestimiento enterico. - Google Patents

Forma de dosificacion que comprende un agente alcalino y una capa de revestimiento enterico.

Info

Publication number
MX2022007162A
MX2022007162A MX2022007162A MX2022007162A MX2022007162A MX 2022007162 A MX2022007162 A MX 2022007162A MX 2022007162 A MX2022007162 A MX 2022007162A MX 2022007162 A MX2022007162 A MX 2022007162A MX 2022007162 A MX2022007162 A MX 2022007162A
Authority
MX
Mexico
Prior art keywords
coating layer
alkaline agent
dosage form
enteric coating
icl
Prior art date
Application number
MX2022007162A
Other languages
English (en)
Inventor
Vinay Jain
Ashish Guha
Shraddha Joshi
Priyanka Haksar
Umesh Kapale
Nilam Bharambe
Original Assignee
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations Gmbh filed Critical Evonik Operations Gmbh
Publication of MX2022007162A publication Critical patent/MX2022007162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una forma de dosificación, que comprende: a) un núcleo, que comprende un ingrediente biológicamente activo, que es estable en un grado de al menos el 95% en pH 3 durante 2 horas a 22°C, b) una capa de revestimiento intermedio (ICL) sobre o por encima del núcleo, que comprende un agente alcalino, y c) una capa de revestimiento entérico (ECL) sobre o por encima de la capa de revestimiento intermedio que comprende un polímero entérico, en donde la relación en porcentaje del agente alcalino en la ICL con respecto al polímero entérico en la ECL es del 5 al 95% cuando se calcula por medio de la fórmula: (ver Fórmula).
MX2022007162A 2019-12-11 2020-09-17 Forma de dosificacion que comprende un agente alcalino y una capa de revestimiento enterico. MX2022007162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941051238 2019-12-11
PCT/EP2020/075960 WO2021115648A1 (en) 2019-12-11 2020-09-17 Dosage form comprising an alkaline agent and an enteric coating layer

Publications (1)

Publication Number Publication Date
MX2022007162A true MX2022007162A (es) 2022-07-12

Family

ID=72659788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007162A MX2022007162A (es) 2019-12-11 2020-09-17 Forma de dosificacion que comprende un agente alcalino y una capa de revestimiento enterico.

Country Status (10)

Country Link
US (1) US20230000780A1 (es)
EP (1) EP4072533A1 (es)
JP (1) JP2023505714A (es)
KR (1) KR20220113697A (es)
CN (1) CN114828833A (es)
BR (1) BR112022011130A2 (es)
CA (1) CA3160876A1 (es)
IL (1) IL293651A (es)
MX (1) MX2022007162A (es)
WO (1) WO2021115648A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022011055A2 (pt) 2019-12-11 2022-08-23 Evonik Operations Gmbh Forma de dosagem para uso no tratamento ou na prevenção de uma doença
WO2023137556A1 (en) * 2022-01-20 2023-07-27 Bionxt Solutions Inc. Chemical composition for enteric drug delivery
WO2023174722A1 (en) 2022-03-15 2023-09-21 Evonik Operations Gmbh Pre-functionalized hard shell capsule with accelerated drug release at ph value 5 to 5.5
WO2023214016A1 (en) * 2022-05-06 2023-11-09 Evonik Operations Gmbh Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US20050214371A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
SI2152250T1 (sl) 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
CN102626398A (zh) * 2012-04-18 2012-08-08 上海腾瑞制药有限公司 一种泮托拉唑钠肠溶片及其制备方法
MX2015000395A (es) * 2012-07-12 2015-04-10 Novus Int Inc Composiciones de matriz y capa para proteccion de bioactivos.
CA2910865C (en) * 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CN105640915A (zh) * 2016-03-02 2016-06-08 吉林修正药业新药开发有限公司 一种雷贝拉唑钠肠溶片及其制备工艺

Also Published As

Publication number Publication date
KR20220113697A (ko) 2022-08-16
IL293651A (en) 2022-08-01
BR112022011130A2 (pt) 2022-08-23
WO2021115648A1 (en) 2021-06-17
EP4072533A1 (en) 2022-10-19
JP2023505714A (ja) 2023-02-10
CA3160876A1 (en) 2021-06-17
CN114828833A (zh) 2022-07-29
US20230000780A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
MX2022007162A (es) Forma de dosificacion que comprende un agente alcalino y una capa de revestimiento enterico.
NZ572760A (en) A delayed release drug formulation comprising a coating comprising a low amylose starch and a Eudragit acrylate polymer
BR0013720A (pt) Formulação em pelota de liberação controlada
CO2021015624A2 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos
MX2009012030A (es) Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento.
BR112013020132A2 (pt) lenço para uso com uma solução germicida e método para desinfetar uma superfície
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2020012369A (es) Composición fungicida estabilizada.
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
NZ599762A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
MX2018011974A (es) Composicion para controlar microsporidia en peces y metodo para controlar microsporidia en peces utilizando la misma.
CA3156474A1 (en) GPR52 MODULATING COMPOUNDS
RS54766B1 (sr) Prolekovi 6-cikloheksil-1-hidroksi-4-metilpiridin-2(1h)-ona i njegovih derivata
PH12021550389A1 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2009006638A (es) Agente para erradicar helicobacter pylori que tiene actividad inhibidora sobre la secrecion de acido gastrico.
EP4360473A3 (en) Aerosol-generating film
MX2022007160A (es) Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.
BR112022005430A2 (pt) Composição aquosa de revestimento de sementes, uso da composição, semente revestida, e, método para revestimento
MX2007011814A (es) Compuestos citoesqueleticos activos, composiciones y usos.
MX2021014309A (es) Composicion para alimentos de animales que contiene los compuestos del componente hexahidro-?-acido y aplicacion de la misma.
MX354575B (es) Uso de depósito de fosfolípidos viscosos estables en almacenamiento para tratar heridas..
ZA201905664B (en) Novel dosage form
WO2020053275A3 (en) Animal feed composition comprising muramidase and use thereof
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect